Mylan introduces new antiepileptic drug

Mylan Institutional business has launched Levetiracetam in Sodium Chloride Injection of multiple strengths, 500mg/100ml, 1000mg/100ml and 1500mg/100ml, for intravenous use.

Levetiracetam in sodium chloride injection is an antiepileptic drug indicated for adults with different seizure types when oral administration is temporarily not feasible.

The drug is used to treat partial onset seizures, myoclonic seizures in patients with juvenile myoclonic epilepsy, primary generalized tonic-clonic seizures.

Mylan CEO Heather Bresch said that they are the first company to offer three strengths of Levetiracetam in ready-to-administer bags, which assist in the ease, accuracy and convenience of dosing.

“The launch reflects our commitment to innovate to meet unmet needs and our strategy of expanding Mylan’s product portfolio across the generic, specialty and niche market segments,” Bresch added.

Mylan Institutional president Matt Erick said the addition of the product supports their business strategy to partner with customers and increase their efficiency by offering quality and convenience in one package.